Skip to main content
. Author manuscript; available in PMC: 2019 Sep 15.
Published in final edited form as: Clin Cancer Res. 2018 May 23;24(18):4380–4387. doi: 10.1158/1078-0432.CCR-18-0613

Figure 2. Antitumor activity of taselisib plus fulvestrant in patients with measurable or evaluable disease at baseline (safety evaluable population).

Figure 2

PD, progressive disease; PR, partial response; SD, stable disease; SLD, sum of the longest diameter